UNSPSC 51152018: Butamisole

This classification denotes an antihelminthic agent with the molecular formula C15H19N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XVB7982801, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thiazol-6-yl)phenyl)-, (-)- but generally known as butamisole, which bears US NIH Compound Identifier 166572. Butamisole most often comes in base and hydrochloride forms. European Medicines Agency schedules Butamisole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06001MIG.

UNSPSC 51152018 Butamisole is a Commodity code that covers pharmaceutical and chemical compounds used in veterinary and human medicine, though recent state and local procurement activity under this code shows minimal relevant alignment with the code's nominal scope. The single recent opportunity posted does not reflect butamisole procurement; instead, Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems — opioid-reversal medications and harm-reduction equipment — which fall outside the butamisole commodity classification. This mismatch suggests either a tagging error in the state procurement record or that state and local jurisdictions are using this code infrequently or not at all for butamisole-specific sourcing.

The Seminole County opportunity (IFB 60459723LAS, response deadline July 26, 2023) reflects a public health and emergency-response use case rather than a butamisole procurement. The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with potential FEMA funding and a two-year initial contract term plus one-year renewal option. Vendors were required to provide fixed-fee pricing, comply with E-Verify and drug-free workplace certification, carry commercial general liability and professional liability insurance, and accept a three-month probationary termination clause. This opportunity represents community health and harm-reduction sourcing rather than butamisole procurement, and the code shows no other documented state or local opportunities in the recent record.